Claims for Patent: 7,947,654
✉ Email this page to a colleague
Summary for Patent: 7,947,654
| Title: | Pharmaceutical formulations |
| Abstract: | Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary noctural enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way. |
| Inventor(s): | Nilsson; Anders (Lund, SE), Lindner; Hans (Leichlingen, DE), Wittendorff; Jorgen (Hvidovre, DK) |
| Assignee: | Ferring B.V. (Hoofddorp, NL) |
| Application Number: | 12/487,116 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,947,654 |
| Patent Claims: |
1. A solid orodispersible pharmaceutical dosage form comprising from 10 to 600 .mu.g desmopressin acetate, measured as the free base, which solid orodispersible dosage
form disintegrates in the mouth within 10 seconds.
2. The dosage form as claimed in claim 1, which is adapted for sublingual administration. 3. The dosage form as claimed in claim 1, wherein the dosage form is obtainable by subliming solvent from a composition comprising desmopressin acetate and a solution of carrier material in a solvent, the composition being in the solid state in a mold. 4. The dosage form as claimed in claim 3, wherein the sublimation is carried out by freeze drying a composition comprising desmopressin acetate and a solution of the carrier material in a solvent. 5. The dosage form as claimed in claim 1, which comprises an open matrix network carrying the desmopressin acetate, the open matrix network being comprised of a water-soluble or water-dispersable carrier material that is inert towards desmopressin. 6. The dosage form as claimed in claim 5, wherein the open matrix network comprises gelatin. 7. The dosage form as claimed in claim 6, wherein the gelatin is fish gelatin. 8. The dosage form as claimed in claim 7, wherein the fish gelatin is non-gelling. 9. A pack comprising an orodispersible solid pharmaceutical dosage form as defined in claim 1 together with instructions to place the dosage form in a patient's mouth beneath the tongue (for sublingual administration). |
